Loading...
XNASACAD
Market cap2.82bUSD
Dec 27, Last price  
16.95USD
1D
-2.42%
1Q
8.03%
Jan 2017
-41.23%
Name

ACADIA Pharmaceuticals Inc

Chart & Performance

D1W1MN
XNAS:ACAD chart
P/E
—
P/S
3.88
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
5.29%
Rev. gr., 5y
26.55%
Revenues
726m
+40.45%
4,604,30010,956,3008,133,0007,555,0001,590,0006,399,00042,135,0002,067,0004,907,0001,145,000120,00061,00017,331,000124,901,000223,807,000339,076,000441,755,000484,145,000517,235,000726,437,000
Net income
-61m
L-71.62%
-25,917,100-34,135,100-45,048,000-56,390,000-64,244,000-45,145,00015,139,000-22,765,000-20,849,000-37,948,000-92,475,000-164,443,000-271,393,000-289,403,000-245,192,000-235,259,000-281,584,000-167,870,000-215,975,000-61,286,000
CFO
17m
P
-20,693,400-20,262,600-41,418,000-54,926,000-64,869,000-13,727,000-10,703,000-19,897,000-21,633,000-31,769,000-66,434,000-121,795,000-210,408,000-217,857,000-167,470,000-151,130,000-136,166,000-125,660,000-114,035,00016,702,000
Earnings
Feb 25, 2025

Profile

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
URL
https://acadia.com/
IPO date
May 27, 2004
Employees
540
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
726,437
40.45%
517,235
6.83%
484,145
9.60%
Cost of revenue
799,816
740,831
696,384
Unusual Expense (Income)
NOPBT
(73,379)
(223,596)
(212,239)
NOPBT Margin
Operating Taxes
10,250
2,531
351
Tax Rate
NOPAT
(83,629)
(226,127)
(212,590)
Net income
(61,286)
-71.62%
(215,975)
28.66%
(167,870)
-40.38%
Dividends
Dividend yield
Proceeds from repurchase of equity
25,129
8,199
18,162
BB yield
-0.49%
-0.32%
-0.48%
Debt
Debt current
9,405
9,305
8,304
Long-term debt
105,005
105,390
112,252
Deferred revenue
Other long-term liabilities
15,147
9,074
7,034
Net debt
(330,225)
(315,098)
(409,520)
Cash flow
Cash from operating activities
16,702
(114,035)
(125,660)
CAPEX
(40,050)
(1,122)
Cash from investing activities
31,998
73,241
(71,102)
Cash from financing activities
25,129
8,199
18,162
FCF
(78,502)
(212,053)
(231,814)
Balance
Cash
438,865
416,823
520,706
Long term investments
5,770
12,970
9,370
Excess cash
408,313
403,931
505,869
Stockholders' equity
(2,430,797)
(2,370,510)
(2,153,752)
Invested Capital
2,934,904
2,841,620
2,766,110
ROIC
ROCE
EV
Common stock shares outstanding
163,819
161,683
160,493
Price
31.31
96.67%
15.92
-31.79%
23.34
-56.34%
Market cap
5,129,173
99.27%
2,573,993
-31.29%
3,745,907
-55.46%
EV
4,798,948
2,258,895
3,336,387
EBITDA
(67,827)
(221,570)
(208,895)
EV/EBITDA
Interest
6,610
Interest/NOPBT